Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Transoral surgery and neck dissection with deintensified risk-based post-operative management increases efficacy in oropharynx cancer

Dr Barbara Burtness - Yale School of Medicine, New Haven, USA
Transoral surgery and neck dissection with deintensified risk-based post-operative management increases efficacy in oropharynx cancer ( Dr Barbara Burtness - Yale School of Medicine, New Haven, USA )
3 Jun 2024

Osimertinib success in locally advanced EGFR-mutated NSCLC

Dr Suresh Ramalingam - Emory University School of Medicine, Atlanta, USA
Osimertinib success in locally advanced EGFR-mutated NSCLC ( Dr Suresh Ramalingam - Emory University School of Medicine, Atlanta, USA )
3 Jun 2024

Adjuvant avelumab versus control does not significantly improve DFS but does improve OS in high-risk TNBC patients

Prof Pier Conte - University of Padova, Padova, Italy
Adjuvant avelumab versus control does not significantly improve DFS but does improve OS in high-risk TNBC patients ( Prof Pier Conte - University of Padova, Padova, Italy )
3 Jun 2024

Adagrasib improves on docetaxel in previously treated NSCLC

Dr Robert Jotte - Rocky Mountain Cancer Centers, Colorado
Adagrasib improves on docetaxel in previously treated NSCLC ( Dr Robert Jotte - Rocky Mountain Cancer Centers, Colorado )
3 Jun 2024

Maintenance systemic therapy versus local consolidative therapy plus maintenance systemic therapy for NSCLC

Dr Puneeth Iyengar - Memorial Sloan Kettering Cancer Center, New York, USA
Maintenance systemic therapy versus local consolidative therapy plus maintenance systemic therapy for NSCLC ( Dr Puneeth Iyengar - Memorial Sloan Kettering Cancer Center, New York, USA )
3 Jun 2024

Manageable safety profile with early efficacy of Tec-DR in NDMM

Prof Salomon Manier - Hospital Center University De Lille, Lille, France
Manageable safety profile with early efficacy of Tec-DR in NDMM ( Prof Salomon Manier - Hospital Center University De Lille, Lille, France )
3 Jun 2024

Inavolisib, palbociclib, fulvestrant combo shows sustained benefit beyond disease progression in HER2‑negative metastatic breast cancer

Dr Dejan Juric - Massachusetts General Hospital, Boston, USA
Inavolisib, palbociclib, fulvestrant combo shows sustained benefit beyond disease progression in HER2‑negative metastatic breast cancer ( Dr Dejan Juric - Massachusetts General Hospital, Boston, USA )
3 Jun 2024

Neoadjuvant sacituzumab govitecan shows promising activity in muscle-invasive urothelial bladder cancer

Dr Antonio Cigliola - IRCCS San Raffaele Hospital, Milan, Italy
Neoadjuvant sacituzumab govitecan shows promising activity in muscle-invasive urothelial bladder cancer ( Dr Antonio Cigliola - IRCCS San Raffaele Hospital, Milan, Italy )
2 Jun 2024

Rates of pathologic complete response after neoadjuvant datopotamab deruxtecan in neoadjuvant breast cancer

Dr Jane Lowe Meisel - Winship Canter Institute, Atlanta, USA
Rates of pathologic complete response after neoadjuvant datopotamab deruxtecan in neoadjuvant breast cancer ( Dr Jane Lowe Meisel - Winship Canter Institute, Atlanta, USA )
2 Jun 2024

Lutetium-177–PSMA-617 improves self-reported pain and HRQoL in taxane-naïve patients with PSMA-positive mCRPC

Prof Karim Fizazi - Institut Gustave Roussy, Villejuif, France
Lutetium-177–PSMA-617 improves self-reported pain and HRQoL in taxane-naïve patients with PSMA-positive mCRPC ( Prof Karim Fizazi - Institut Gustave Roussy, Villejuif, France )
2 Jun 2024

Daratumumab plus bortezomib/lenalidomide/dexamethasone in transplant-eligible patients with NDMM: MRD analysis

Dr Paula Rodríguez-Otero - Clinica Universidad de Navarra, Pamplona, Spain
Daratumumab plus bortezomib/lenalidomide/dexamethasone in transplant-eligible patients with NDMM: MRD analysis ( Dr Paula Rodríguez-Otero - Clinica Universidad de Navarra, Pamplona, Spain )
2 Jun 2024

Melanoma outcomes improved by dual immunotherapy before surgery rather than after

Prof Christian Blank - Netherlands Cancer Institute, Amsterdam, Netherlands
Melanoma outcomes improved by dual immunotherapy before surgery rather than after ( Prof Christian Blank - Netherlands Cancer Institute, Amsterdam, Netherlands )
2 Jun 2024